Pharming Group (PHAR) Stock Statistics & Valuation Metrics

Pharming Group has a market cap or net worth of $910.28M. The enterprise value is $980.93M.

Pharming Group has 70,625,230 shares outstanding. The number of shares has decreased by -2.65% in one year.

Pharming Group’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is 0.97%.

The current PE Ratio of Pharming Group is ―. Pharming Group’s PEG ratio is -3.57.

In the last 12 months, Pharming Group had revenue of 377.18M and earned 2.86M in profits. Earnings per share was 0.04.

In the last 12 months, operating cash flow was 50.77M and capital expenditures -704.82K, giving a free cash flow of 50.07M billion.

Pharming Group pays an annual dividend of ―, resulting in a dividend yield of ―

Pharming Group upcoming earnings date is Jul 30, 2026, Before Open (Confirmed).

Pharming Group as a current ratio of 2.59, with Debt / Equity ratio of 43.21%

In the past 12 months, Pharming Group has paid 10.34M in taxes.

Pharming Group EV to EBITDA ratio is 40.17, with an EV/FCF ratio of 24.94.

Pharming Group has $170.90M in cash and marketable securities with $116.20M in debt, giving a net cash position of $54.70M billion.

Gross margin is 88.12%, with operating margin of 5.13%, and net profit margin of 0.76%.

The average price target for Pharming Group is $38.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy